J

ERUSALEM — The chief executive of Teva Pharmaceuticals on Thursday said he is making “strong progress” on the company’s restructuring plan, even as the company posted a huge loss and forecast a challenging 2018.

In an interview, CEO Kare Schultz said he remained confident about the company’s long-term prospects, laying out a two-year turnaround timeline and predicting a “clear move upward” in 2020.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.